UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of November 2026
Commission File Number: 001-38885
ORGANIGRAM GLOBAL INC.
(Translation of registrant’s name into English)
145 King Street West, Suite 1400
Toronto, Ontario ,Canada M5H 1J8
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ ] Form 40-F [ X ]
SUBMITTED HEREWITH
Exhibits
| | | | | |
99.1 | News Release dated November 13, 2026 |
| |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
ORGANIGRAM GLOBAL INC.
/s/ Greg Guyatt
Greg Guyatt
Chief Financial Officer
Date: November 13, 2026
Organigram Provides NASDAQ Listing Update
The Notification has no immediate effect on the listing or trading of the Company's common shares on the Nasdaq Global Select Market.
TORONTO, ON, November 13, 2026 – Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI) (the “Company” or “Organigram”), Canada's #1 cannabis company by market share¹ and a growing global cannabis platform, today announced that on November 11, 2026, it received notification (the “Notification”) from The Nasdaq Stock Market LLC (“Nasdaq”) that it is not in compliance with the minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1) for continued listing on the Nasdaq Global Select Market. The Notification was issued because the closing bid price of the Company's common shares was below US$1.00 per share for 30 consecutive business days. Nasdaq Listing Rule 5450(a)(1) requires listed common shares to maintain a minimum bid price of US$1.00 per share (the “Minimum Bid Requirement”), while Nasdaq Listing Rule 5810(c)(3)(A) provides that a deficiency exists when the requirement is not met for 30 consecutive business days.
The Notification has no immediate effect on the listing or trading of the Company's common shares on the Nasdaq Global Select Market. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 calendar days, until May 10, 2027, to regain compliance with the Minimum Bid Requirement. To regain compliance, the closing bid price of the Company's common shares must be at least US$1.00 per share for a minimum of 10 consecutive business days during the compliance period, subject to Nasdaq's discretion to extend this period.
If the Company does not regain compliance by May 10, 2027, it may be eligible for an additional 180-calendar-day compliance period, subject to satisfying applicable Nasdaq requirements, including transferring its listing to the Nasdaq Capital Market. If the Company does not qualify for an additional compliance period, its common shares may become subject to delisting proceedings, subject to applicable appeal rights.
The Company's common shares are also listed on the Toronto Stock Exchange, and the Notification does not affect the Company's listing or compliance status on that exchange.
About Organigram
Organigram Global Inc. is listed on the NASDAQ Global Select Market and TSX. The Company's wholly owned subsidiary, Organigram Inc., is a licensed cultivator and processor. Through its acquisition of Sanity Group GmbH ("Sanity Group"), Organigram participates in the German medical cannabis market and other emerging markets within Europe. Organigram is focused on producing high-quality cannabis for adult consumers, as well as extending the Company's global footprint. Organigram has also developed and acquired a portfolio of cannabis brands, including Edison, Big Bag O' Buds, SHRED, Monjour, Tremblant, Collective Project, Trailblazer, BOXHOT and DEBUNK. Through its acquisition of Sanity Group, Organigram's European brands include Vayamed, avaay, ZOIKS, Endosane Pharmaceuticals,
VAAY, and Grashaus Projects. Organigram operates facilities in Moncton, New Brunswick and Lac Supérieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba. The Company also operates two additional cannabis processing facilities in Southwestern Ontario; one in Aylmer and the other in London. The facility in Aylmer houses best-in-class extraction capabilities, and is optimized for formulation refinement, post-processing of minor cannabinoids, and infused pre-roll production. The facility in London will be optimized for labelling, packaging, and national fulfillment. The Company is regulated by Health Canada under the Cannabis Act and the Cannabis Regulations.
Contacts
For Investor enquiries:
Max Schwartz, Director of Investor Relations
investors@organigram.ca